STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial
Matthew J. Reilley(University of Virginia Health System), David S. Hong(The University of Texas MD Anderson Cancer Center), Samantha J. Lee(Ionis Pharmaceuticals (United States)), Xiaokun Xiao(Ionis Pharmaceuticals (United States)), Richard Woessner(AstraZeneca (United States)), Paul D. Lyne(AstraZeneca (South Korea)), Sarina A. Piha‐Paul(The University of Texas MD Anderson Cancer Center), Luis Fayad(The University of Texas MD Anderson Cancer Center), Nathan Fowler(Repligen (United States)), Brett P. Monia(Ionis Pharmaceuticals (United States)), Minji Jo(Japanese Foundation For Cancer Research), Razelle Kurzrock(Medical College of Wisconsin), John Nemunaitis(Gradalis (United States)), Joanna Schmidt(Ionis Pharmaceuticals (United States)), Carl Cook(AstraZeneca (South Korea)), Mason Yamashita(Ionis Pharmaceuticals (United States)), Patricia McCoon(AstraZeneca (Brazil)), Qinying Liu(Fujian Medical University), Michael A. Curran(The University of Texas MD Anderson Cancer Center), Anas Younes(Intercept Pharmaceuticals (United States)), Steven G. Hughes(Ionis Pharmaceuticals (United States)), Youngsoo Kim(Ajou University), Tianyuan Zhou(Ionis Pharmaceuticals (United States)), A. Robert MacLeod(Ionis Pharmaceuticals (United States)), Alexey S. Revenko(Ionis Pharmaceuticals (United States)), Murali V.P. Nadella(AstraZeneca (South Korea)), Jeff Hsu(Ionis Pharmaceuticals (United States))
Cited by 286
Related Papers
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
|Molecular Cancer Therapeutics|2015|2.3k
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k